Induction of apoptosis in HeLa cells by trans-activation-deficient p53

Genes and Development

Volumn 9, Issue 17, 1995, Pages 2170-2183

  Haupt, Ygal ^a   Rowan, Sheldon ^a   Shaulian, Eitan ^a   Vousden, Karen H ^b,c   Oren, Moshe ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

^b LUDWIG INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

apoptosis; p53; tumor suppression; TUNEL

Indexed keywords

PROTEIN P53;

ANIMAL CELL; APOPTOSIS; ARTICLE; CONTROLLED STUDY; DELETION MUTANT; GENE MUTATION; HELA CELL; HUMAN; HUMAN CELL; NONHUMAN; ONCOGENE MYC; ONCOGENE RAS; PRIORITY JOURNAL; RAT; TRANSCRIPTION INITIATION; TUMOR SUPPRESSOR GENE;

ANIMALIA; MURINAE;

EID: 0029092356     PISSN: 08909369     EISSN: None     Source Type: Journal    
DOI: 10.1101/gad.9.17.2170     Document Type: Article

References (101)

1. Baker, S.J., S. Markowitz, E.R. Fearson, J.K.V. Willson, and B. Vogelstein. 1990. Suppression of human colorectal carcinoma cell growth by wild-type p53. Science 249: 912-915.
2. Barak, Y., E. Gottlieb, T. Juven-Gershon, and M. Oren. 1994. Regulation of mdm2 expression by p53: Alternative promoters produce transcripts with nonidentical translation potential. Genes & Dev. 8: 1739-1749.
3. Berns, A. 1994. Is p53 the only real tumor suppressor gene? Curr. Biol. 4: 137-139.
4. Caelles, C., A. Helmberg, and M. Karin. 1994. p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. Nature 370: 220-223.
5. Canman, C.E., T.M. Gilmer, S.B. Coutts, and M.B. Kastan. 1995. Growth factor modulation of p53-mediated growth arrest versus apoptosis. Genes & Dev. 9: 600-611.
6. Chen, J.D., V. Marechal, and A.J. Levine. 1993. Mapping of the p53 and mdm-2 interaction domains. Mol. Cell Biol. 13: 4107-4114.
7. Chiou, S.-K., L. Rao, and E. White. 1994. Bcl-2 blocks p53-dependent apoptosis. Mol. Cell Biol. 14: 2556-2563.
8. Clarke, A.R., S. Gledhill, M.L. Hooper, C.C. Bird, and A.H. Wyllie. 1994. p53 dependence or early apoptotic and proliferative responses within the mouse intestinal epithelium following gamma-irradiation. Oncogene 9: 1767-1773.
9. Crook, T., J.P. Morgenstern, L. Crawford, and L. Banks. 1989. Continued expression of HPV-16 E7 protein is required for maintenance of the transformed phenotype of cells co-transfected by HPV-16 plus EJ-ras. EMBO J. 8: 513-519.
10. Crook, T., N.J. Marston, E.A. Sara, and K.H. Vousden. 1994. Transcriptional activation by p53 correlates with suppression of growth but not transformation. Cell 79: 817-827.
11. Darzynkiewicz, Z., S. Bruno, G. Delbino, W. Gorczyca, M.A. Hotz, P. Lassota, and F. Traganos. 1992. Features of apoptotic cells measured by flow cytometry. Cytometry 13: 795-808.
12. Debbas, M. and E. White. 1993. Wild-type p53 mediates apoptosis by E1A, which is inhibited by E1B. Genes & Dev. 7: 546-554.
13. Demers, G.W., S.A. Foster, C.L. Halbert, and D.A. Galloway. 1994. Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. Proc. Natl. Acad. Sci.. 91: 4382-4386.
14. Donehower, L.A. and A. Bradley. 1993. The tumor suppressor p53. Biochim. Biophys. Acta 1155: 181-205.
15. Dulic, V., W.K. Kaufmann, S.J. Wilson, T.D. Tlsty, E. Lees, J.W. Harper, S.J. Elledge, and S.I. Reed. 1994. p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. Cell 76: 1013-1023.
16. Edmonds, C. and K.H. Vousden. 1989. A point mutational analysis of human papillomavirus type 16 E7 protein. J. Virol. 63: 2650-2656.
17. El-Deiry, W.S., T. Tokino, V.E. Velculescu, D.E. Levy, R. Parsons, J.M. Trent, D. Lin, W.E. Mercer, K.W. Kinzler, and B. Vogelstein. 1993. WAF1, a potential mediator of p53 tumor suppression. Cell 75: 817-825.
18. El-Deiry, W.S., J.W. Harper, P.M. O'Connor, V.E. Verculescu, C.E. Canman, J. Jackson, J.A. Pietenopol, M. Burrell, D.E. Hill, Y. Wang, W.K. Wiman, W.E. Mercer, M.B. Kastan, K.W. Kohn, S.J. Elledge, K.W. Kinzler, and B. Vogelstein. 1994. WAF1/CIP1 is induced in p53-mediated G1 arrest and apoptosis. Cancer Res. 54: 1169-1174.
19. Eliyahu, D., N. Goldfinger, O. Pinhasi-Kimhi, G. Shaulsky, Y. Skurnik, N. Arai, V. Rotter, and M. Oren. 1988. Meth A fibrosarcoma cells express two transforming mutant p53 species. Oncogene 3: 313-321.
20. Eliyahu, D., D. Michalovitz, S. Eliyahu, O. Pinhasi-Kimhi, and M. Oren. 1989. Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl Acad. Sci.. 86: 8763-8767.
21. Finlay, C.A., P.W. Hinds, and A.J. Levine. 1989. The p53 protooncogene can act as a suppressor of transformation. Cell 57: 1083-1093.
22. Friend, S. 1994. p53: A glimpse at the puppet behind the shadow play. Science. 334-335.
23. Gavrieli, Y., Y. Sherman, and S.A. Ben-Sasson. 1992. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119: 493-501.
24. Ginsberg, D., F. Mechta, M. Yaniv, and M. Oren. 1991. Wild-type p53 can down-modulate the activity of various promoters. Proc. Natl. Acad. Sci.. 88: 9979-9983.
25. Gorczyca, W., G. Jianping, and Z. Darzynkiewicz. 1993. Detection of DNA strand breaks in individual apoptotic cells by the in situ terminal deoxynucleotidyl transferase and nick translation assays. Cancer Res. 53: 1945-1951.
26. Gottlieb, E., R. Haffner, T. von Ruden, E.F. Wagner, and M. Oren. 1994. Down-regulation of wild-type p53 activity interferes with apoptosis of IL-3-dependent hematopoietic cells following IL-3 withdrawal. EMBO J. 13: 1368-1374.
27. Haffner, R. and M. Oren. 1995. p53: Biochemical properties and biological effects. Curr. Opin. Genet. Dev. 5: 84-90.
28. Haines, D.S., J.E. Landers, L.J. Engle, and D.L. George. 1994. Physical and functional interaction between wild-type p53 and mdm2 proteins. Mol. Cell Biol. 14: 1171-1178.
29. Haldar, S., M. Negrini, M. Monne, S. Sabbioni, and C.M. Croce. 1994. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 54: 2095-2097.
30. Halevy, O., D. Michalovitz, and M. Oren. 1990. Different tumor derived p53 mutants exhibit distinct biological activities. Science 250: 113-116.
31. Harper, J.W., G.R. Adami, N. Wei, K. Keyomarsi, and S.J. Elledge. 1993. The p21 CDK-Interacting protein cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75: 805-816.
32. Harris, C.C. and M. Hollstein. 1993. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med. 329: 1318-1327.
33. Haupt, Y., S. Rowan, and M. Oren. 1995. p53-mediated apoptosis in HeLa cells can be overcome by excess pRB. Oncogene 10: 1563-1571.
34. Hermeking, H. and D. Eick. 1994. Mediation of c-myc-induced apoptosis by p53. Science 265: 2091-2093.
35. Hickman, E.S., S.M. Picksley, and K.H. Vousden. 1994. Cells expressing HPV16 E7 continue cell cycle progression following DNA damage induced p53 activation. Oncogene 9: 2177-2181.
36. Hinds, P.W., C.A. Finlay, S.J. Quartin, E.R. Baker, B. Fearon, B. Vogelstein, and A.J. Levine. 1990. Mutant p53 DNA clones from human colon carcinomas cooperate with ras in transforming primary rat cells - a comparison of the hot spot mutant phenotype. Cell Growth Differ. 1: 571-580.
37. Hoppe-Seyler, F. and K. Butz. 1993. Repression of endogenous p53 transactivation function in HeLa cervical carcinoma cells by human papillomavirus Type-16 E6, human MDM-2, and mutant p53. J. Virol. 67: 3111-3117.
38. Howes, K.A., N. Ransom, D.S. Papermaster, J.G.H. Lasudry, D.M. Albert, and J.J. Windle. 1994. Apoptosis or retinoblastoma: Alternative fates of photoreceptors expressing the HPV-16 E7 gene in the presence or absence of p53. Oncogene 8: 1300-1310.
39. Ishioka, C., C. Englert, P. Winge, Y.-X. Yan, M. Engelstein, and S.H. Friend. 1995. Mutational analysis of the carboxy-terminal portion of p53 using both yeast and mammalian cell assays in vivo. Oncogene 10: 1485-1492.
40. Jochemsen, A.G., J.L. Bos, and A.J. van der Eb. 1984. The first exon of region E1A genes of adenovirus 5 and 12 encodes a separate functional protein domain. EMBO J. 3: 2293-2297.
41. Johnson, P., S. Chung, and S. Benchimol. 1993. Growth suppression of Friend virus-transformed erythroleukemia cells by p53 protein is accompanied by hemoglobin production and is sensitive to erythropoietin. Mol. Cell Biol. 13: 1456-1463.
42. Juven, T., Y. Barak, A. Zauberman, D.L. George, and M. Oren. 1993. Wild type p53 can mediate sequence-specific transactivation of an internal promoter within the mdm2 gene. Oncogene 8: 3411-3416.
43. Kastan, B.M., Q. Zhan, W.S. El-Deiry, F. Carrier, T. Jacks, W.V. Walsh, B.S. Plunkett, B. Vogelstein, and A.J. Fornace. 1992. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. Cell 71: 587-597.
44. Kern, S.E., K.W. Kinzler, A. Bruskin, D. Jarosz, P. Friedman, C. Prives, and B. Vogelstein. 1991. Identification of p53 as a sequence-specific DNA-binding protein. Science 252: 1708-1711.
45. LaFlamme, S.E., S.K. Akiyama, and K. Yamada. 1992. Regulation of fibronectin receptor distribution. J. Cell Biol. 117: 437-447.
46. Levine, A.J. 1993. The tumor suppressor genes. Annu. Rev. Biochem. 62:623-651.
47. Lin, J.Y., J.D. Chen, B. Elenbaas, and A.J. Levine. 1994. Several Hydrophobic amino acids in the p53 amino-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55-kD protein. Genes & Dev. 8: 1235-1246.
48. Lotem, J. and L. Sachs. 1993. Hematopoietic cells from mice deficient in wild-type p53 are more resistant to induction of apoptosis by some agents. Blood 82: 1092-1096.
49. Lowe, S.W. and H.E. Ruley. 1993. Stabilization of the p53 tumor suppressor is induced by adenovirus-5 E1A and accompanies apoptosis. Genes & Dev. 7: 535-545.
50. Lowe, S.W., H.E. Ruley, T. Jacks, and D.E. Housman. 1993. p53-dependent apoptosis modulates the cytotoxicity of anti-cancer agents. Cell 74: 957-967.
51. Mack, D.H., J. Vartikar, J.M. Pipas, and L.A. Laimins. 1993. Specific repression of TATA-mediated but not initiator-mediated transcription by wild-type-p53. Nature 363: 281-283.
52. Marston, N.J., T. Crook, and K.H. Vousden. 1994. Interaction of p53 with MDM2 is independent of e6 and does not mediate wild type transformation suppressor function. Oncogene 9: 2707-2716.
53. Michalovitz, D., O. Halevy, and M. Oren. 1990. Conditional inhibition of transformation and of cell proliferation by temperature-sensitive mutant of p53. Cell 62: 671-680.
54. Miyashita, T. and J.C. Reed. 1995. Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. Cell 80: 293-299.
55. Miyashita, T., S. Krajewski, M. Krajewska, H.W. Wang, H.K. Lin, D.A. Liebermann, B. Hoffman, and J.C. Reed. 1994. Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo. Oncogene 9: 1799-1805.
56. Morgenbesser, S.D., B.O. Williams, T. Jacks, and R.A. DePinho. 1994. p53-dependent apoptosis produced by Rb-deficiency in the developing mouse lens. Nature 371: 72-74.
57. Okamoto, K. and D. Beach. 1994. Cyclin G is a transcriptional target of the p53 tumor suppressor protein. EMBO J. 13: 4816-4822.
58. Oliner, J.D., J.A. Pietenpol, S. Thiagalingam, J. Gvuris, K.W. Kinzler, and B. Vogelstein. 1993. Oncoprotein MDM2 conceals the activation domain of tumour suppressor-p53. Nature 362: 857-860.
59. Oren, M. 1992. p53 - The ultimate tumor suppressor gene. FASEB J. 6: 3169-3176.
60. _. 1994. Relationship of p53 to the control of apoptotic cell death. Semin. Cancer Biol. 5: 305.1-305.7.
61. Ory, K., Y. Legros, C. Auguin, and T. Soussi. 1994. Analysis of the most representative tumor-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. EMBO J. 13: 3496-3504.
62. Pan, H. and A.E. Griep. 1994. Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: Implications for tumor suppressor gene function in development. Genes & Dev. 8: 1285-1299.
63. Pavletich, N.P., K.A. Chambers, and C.O. Pabo. 1993. The DNA-binding domain of p53 contains the 4 conserved regions and the major mutation hot spots. Genes & Dev. 7: 2556-2564.
64. Pietenpol, J.A., T. Tokino, S. Thiagalingam, W.S. El-Deiry, K.W. Kinzler, and B. Vogelstein. 1994. Sequence-specific transcriptional activation is essential for growth suppression by p53. Proc. Natl. Acad. Sci. 91: 1998-2002.
65. Pinhasi-Kimhi, O., A. Michalovitz, A. Ben-Zeev, and M. Oren. 1986. Specific interaction between the p53 cellular tumour antigen and major heat shock proteins. Nature 320: 182-185.
66. Prives, C. 1994. How loops, beta sheets, and alpha helices help us to understand p53. Cell 78: 543-546.
67. Qin, X.-Q., D.M. Livingston, W.J. Kaelin, and P.D. Adams. 1994. Deregulated transcription factor E2F-1 expression leads to S-phase entry and p53-mediated apoptosis. Proc. Natl. Acad. Sci. 91: 10918-10922.
68. Ramqvist, T., K.P. Magnusson, Y.S. Wang, L. Szekely, G. Klein, and K.G. Wiman. 1993. Wild-type p53 induced apoptosis in a Burkitt lymphoma (BL) line that carries mutant p53. Oncogene 8: 1495-1500.
69. Reed, M., Y. Wang, G. Mayr, M.E. Enderson, J.F. Schwedes, and P. Tegtmeyer. 1993. p53 domains: Suppression, transformation, and transactivation. Gene Exp. 3: 95-106.
70. Ryan, J.J., R. Danish, C.A. Gottlieb, and M.F. Clarke. 1993. Cell cycle analysis of p53-induced cell death in murine erythroleukemia cells. Mol. Cell Biol. 13: 711-719.
71. Sabbatini, P., S.K. Chiou, L. Rao, and E. White. 1995. Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein. Mol. Cell Biol. 15: 1060-1070.
72. Santhanam, U., A. Ray, and P.B. Sehgal. 1991. Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc. Natl. Acad. Sci. 88: 7605-7609.
73. Selvakumaran, M., H.K. Lin, T. Miyashita, H.G. Wang, S. Krajewski, J.C. Reed, B. Hoffman, and D. Liebermann. 1994. Immediate early up-regulation of bax expression by p53 but not TGF beta 1: A paradigm for distinct apoptotic pathways. Oncogene 9: 1791-1798.
74. Shaulian, E., A. Zauberman, D. Ginsberg, and M. Oren. 1992. Identification of a minimal transforming domain of p53: Negative dominance through abrogation of sequence-specific DNA binding. Mol. Cell Biol. 12: 5581-5592.
75. Shaulian, E., A. Zauberman, J. Milner, E.A. Davies, and M. Oren. 1993. Tight DNA binding and oligomerization are dispensable for the ability of p53 to transactivate target genes and suppress transformation. EMBO J. 12: 2789-2797.
76. Shaulian, E., I. Haviv, Y. Shaul, and M. Oren. 1995. Transcriptional repression by the C-terminal domain of p53. Oncogene 10: 671-680.
77. Shaulsky, G., N. Goldfinger, A. Ben-Ze'ev, and V. Rotter. 1990. Nuclear accumulation of p53 protein is mediated by several nuclear localization signals and plays a role in tumorigenesis. Mol. Cell Biol. 10: 6565-6577.
78. Shaw, P., R. Bovey, S. Tardy, R. Sahli, B. Sordat, and J. Costa. 1992. Induction of apoptosis by wild-type p53 in a human colon tumor-derived cell line. Proc. Natl. Acad. Sci. 89: 4495-4499.
79. Shen, Y.Q. and T. Shenk. 1994. Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular bcl-2 protein. Proc. Natl. Acad. Sci.. 91: 8940-8944.
80. Slebos, R.J.C., M.H. Lee, B.S. Plunkett, T.D. Kessis, B.O. Williams, T. Jacks, L. Hedrick, M.B. Kastan, and K.R. Cho. 1994. p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. Proc. Natl. Acad. Sci. 91: 5320-5324.
81. Smith, M.L., I.-T. Chen, Q. Zhan, I. Bae, C.-Y. Chen, T.M. Gilmer, M.B. Kastan, P.M. O'Connor, and A.J. Fornace, Jr. 1994. Interaction of the p53-regulated protein Gadd45 with Proliferating cell nuclear antigen. Science 266: 1376-1380.
82. Soussi, T., C.C. de Fromentel, and P. May. 1990. Structural aspects of the p53 protein in relation to gene evolution. Oncogene 5: 945-952.
83. Sturzbecher, H.W., R. Brain, C. Addison, K. Rudge, M. Remm, M. Grimaldi, E. Keenan, and J.R. Jenkins. 1992. A C-terminal alpha-helix plus basic region motif is the major structural determinant of p53 tetramerization. Oncogene 7: 1513-1523.
84. Subler, M.A., D.W. Martin, and S. Deb. 1992. Inhibition of viral and cellular promoters by human wild-type p53. J. Virol. 66: 4757-4762.
85. Symonds, H., L. Krall, L. Remington, M. Saenz-Robles, S. Lowe, T. Jacks, and T. Van Dyke. 1994. p53-dependent apoptosis suppresses tumor growth and progression in vivo. Cell 78: 703-711.
86. II60. Science 267: 100-104.
87. Unger, T., M.M. Nau, S. Segal, and J.D. Minna. 1992. p53 - A transdominant regulator of transcription whose function is ablated by mutations occurring in human cancer. EMBO J. 11: 1383-1390.
88. Vogelstein, B. and K.W. Kinzler. 1992. p53 function and dysfunction. Cell 70: 523-526.
89. Waga, S., G.J. Hannon, D. Beach, and B. Stillman. 1994. The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. Nature 369: 574-578.
90. waf1/cip1 Genes & Dev. 8: 2817-2830.
91. Wang, Y.S., L. Szekely, I. Okan, G. Klein, and K.G. Wiman. 1993. Wild-type p53-triggered apoptosis is inhibited by bcl-2 in a v-myc-induced T-cell lymphoma line. Oncogene 8: 3427-3431.
92. White, A.E., E.M. Livanos, and T.D. Tlsty. 1994. Differential disruption of genomic integrity and cell cycle regulation in normal human fibroblasts by the HPV oncoproteins. Genes & Dev. 8: 666-677.
93. Wu, X. and A.J. Levine. 1994. p53 and E2F-1 cooperate to mediate apoptosis. Proc. Natl. Acad. Sci.. 91: 3602-3606.
94. Wu, X., J.H. Bayle, D. Olson, and A.J. Levine. 1993. The p53-mdm-2 autoregulatory feedback loop. Genes & Dev. 7: 1126-1132.
95. Xiong, Y., G.J. Hannon, H. Zhang, D. Casso, R. Kobayashi, and D. Beach. 1993. p21 is a universal inhibitor of cyclin kinases. Science 366: 701-704.
96. Yonish-Rouach, E., D. Resnitzky, J. Lotem, L. Sachs, A. Kimchi, and M. Oren. 1991. Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6. Nature 352: 345-347.
97. Yonish-Rouach, E., D. Ginsberg, and M. Oren. 1993. The role of tumour suppressor genes in apoptosis. In Programmed cell death (ed. M. Levin and D. Watters), pp. 187-202. Harwood Academic Publishers, Chur, Switzerland.
98. Yonish-Rouach, E., J. Borde, M. Gotteland, Z. Mishal, A. Viron, and E. May. 1994. Induction of apoptosis by transiently transfected metabolically stable wt p53 in transformed cell lines. Cell Death Differ. 1: 39-47.
99. Zauberman, A., A. Lupo, and M. Oren. 1995. Identification of p53 target genes through immune selection of genomic DNA: The cyclin G gene contains two distinct p53 binding sites. Oncogene (in press).
100. Zhan, Q., S. Fan, I. Bae, C. Guillouf, D.A. Liebermann, P.M. O'Connor, and A.J. Fornace Jr. 1994. Induction of bax by genotoxic stress in human cells correlates with normal p53 status and apoptosis. Oncogene 9: 3743-3751.
101. Zhang, W., X.Y. Guo, G.Y. Hu, W.B. Liu, J.W. Shay, and A.B. Deisseroth. 1994. A temperature-sensitive mutant of human p53. EMBO J. 13: 2535-2544.